New naloxone nasal spray at least doubles the dose
The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products.
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.
Related News Articles
Headline
The Department of Health and Human Services Office for Civil Rights Feb. 13 announced the launch of a program to implement and enforce statutory and regulatory…
Blog
Hospitals and health systems are cornerstones of health care in their communities, providing care and services that go far beyond the walls of their facilities…
Headline
The Assistant Secretary for Technology Policy/Office of the National Coordinator for Health IT released Dec. 22 two proposed rules related to health data,…
Headline
An EY report prepared for the AHA shows that tax-exempt hospitals and health systems delivered $11 in benefits to their communities for every dollar’s worth of…
Headline
The Food and Drug Administration sent a warning letter to Philips last month due to quality violations found at three of its medical device facilities earlier…
Blog
When a nonprofit hospital files the Internal Revenue Service (IRS) Form 990, Schedule H, it reports a wide range of activities and expenditures to demonstrate…